Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-126 · 5 trials · 3 indications
Rater based interview
Rater based interview
An assessment tool which focuses on cognitive function and memory
| Arm | Type | Description |
|---|---|---|
| ABT-126 Low Dose | EXPERIMENTAL | ABT-126 Low Dose |
| ABT-126 High Dose | EXPERIMENTAL | ABT-126 High Dose |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| ABT-126 Middle Dose | EXPERIMENTAL | ABT-126 Middle Dose |
| sugar pill | PLACEBO_COMPARATOR | Placebo |
| ABT-126 Dose 1 | EXPERIMENTAL | - |
| ABT-126 Dose 2 | EXPERIMENTAL | - |
| A. Sugar Pill | PLACEBO_COMPARATOR | - |
| B. ABT-126 | EXPERIMENTAL | - |
| C. ABT-126 | EXPERIMENTAL | - |
| D. donepezil | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-126 | DRUG | ABT-126 Low Dose |
| Placebo | DRUG | Placebo |
| donepezil | DRUG | Active comparator intervention |
Inclusion Criteria: * Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.). * Is clinically stable while receiving a regimen of one or two all...
Top 20 of 24 competitors
ABT-126 is an investigational small molecule being studied for the treatment of Alzheimer's disease and cognitive deficits in schizophrenia. It has been evaluated in Phase 2 clinical trials for these neurological conditions. The drug is not approved and remains in clinical development.
ABT-126 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie has sponsored multiple clinical trials of ABT-126 in Alzheimer's disease and schizophrenia.
ABT-126 is in Phase 2 clinical development. It has completed four Phase 2 trials, including studies in Alzheimer's disease and cognitive deficits in schizophrenia. The drug is investigational and has not received FDA approval.
ABT-126 has completed four Phase 2 trials. These include NCT00948909 and NCT01549834 in mild-to-moderate Alzheimer's disease, and NCT01655680 and NCT01678755 for cognitive deficits in schizophrenia. All trials are completed, with no active trials ongoing.
ABT-126 is the primary name used in clinical trials and publications. No alternative names have been reported for this investigational compound. It is distinct from other drugs and is identified solely by the designation ABT-126 in clinical research.